• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Alto Neuroscience Inc.

    11/14/24 7:00:29 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANRO alert in real time by email
    SC 13G 1 d873145dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2

    (Amendment No.  )*

     

     

    Alto Neuroscience, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    02157Q109

    (CUSIP Number)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 02157Q109    13G    Page 2 of 5 Pages

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Amit Etkin

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     1,461,1301

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     1,461,1301

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,461,1301

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.4%2

    12  

     TYPE OF REPORTING PERSON*

     

     IN

     

    1 

    Consists of: (i) 1,205,465 shares of the Issuer’s common stock and (ii) 255,665 shares of common stock issuable upon the exercise of stock options within 60 days of September 30, 2024. Does not include 34,711 shares of the Issuer’s common stock issuable upon the vesting of an outstanding restricted stock unit which vests in two equal installments on September 1, 2025 and March 1, 2026, subject to the Reporting Person’s continuous service through such vesting date.

    2 

    This percentage is calculated based upon 26,970,168 outstanding shares of the Issuer’s common stock as of November 8, 2024, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024.


    CUSIP No. 02157Q109    13G    Page 3 of 5 Pages

     

    Item 1.

     

    (a)

    Name of Issuer

    Alto Neuroscience, Inc.

     

    (b)

    Address of Issuer’s Principal Executive Offices

    650 Castro Street, Suite 450

    Mountain View, CA 94041

    Item 2.

     

    (a)

    Name of Person Filing

    Amit Etkin

     

    (b)

    Address of Principal Business Office or, if none, Residence

    c/o Alto Neuroscience, Inc.

    650 Castro Street, Suite 450

    Mountain View, CA 94041

     

    (c)

    Citizenship

    United States Citizen.

     

    (d)

    Title of Class of Securities

    Common Stock

     

    (e)

    CUSIP Number

    02157Q109

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE.

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K).


    CUSIP No. 02157Q109    13G    Page 4 of 5 Pages

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned: See responses to Item 9 on the attached cover pages.

     

      (b)

    Percent of class: See the responses to Item 11 on the attached cover pages.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote – See the responses to Item 5 on the attached cover pages.

     

      (ii)

    Shared power to vote or to direct the vote – See the responses to Item 6 on the attached cover pages.

     

      (iii)

    Sole power to dispose or to direct the disposition of – See the responses to Item 7 on the attached cover pages.

     

      (iv)

    Shared power to dispose or to direct the disposition of – See the responses to Item 8 on the attached cover pages.

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable

     

    Item 10.

    Certification

    Not Applicable.


    CUSIP No. 02157Q109    13G    Page 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    November 14, 2024

     

    /s/ Amit Etkin

    Amit Etkin
    Get the next $ANRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANRO

    DatePrice TargetRatingAnalyst
    10/23/2024$29.00 → $4.00Outperform → Neutral
    Wedbush
    10/23/2024Buy → Neutral
    Rodman & Renshaw
    9/3/2024$29.00Outperform
    Wedbush
    2/27/2024Outperform
    William Blair
    2/27/2024Outperform
    TD Cowen
    2/27/2024$32.00Outperform
    Robert W. Baird
    2/27/2024$33.00Buy
    Jefferies
    2/27/2024$32.00Buy
    Stifel
    More analyst ratings

    $ANRO
    SEC Filings

    See more
    • Alto Neuroscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

      6/3/25 6:34:52 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.

      SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

      5/15/25 4:26:21 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Alto Neuroscience Inc.

      SCHEDULE 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      5/15/25 3:19:13 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Manji Husseini

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      5/15/25 4:16:52 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cox Christopher Nixon

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      5/15/25 4:16:40 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director York Gwill

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      5/15/25 4:16:18 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alto Neuroscience Inc.

      SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/14/24 5:46:11 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alto Neuroscience Inc.

      SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/14/24 7:00:29 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alto Neuroscience Inc.

      SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/12/24 9:50:14 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Christopher Nixon Cox Named Chairman of High-Trend International Group

      SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

      3/13/25 9:00:00 AM ET
      $ANRO
      $HTCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Marine Transportation
      Consumer Discretionary
    • Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

      – Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, M

      5/21/24 8:05:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

      – Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies. "Maha joins our Board at a pivotal moment for Alto, as we continu

      3/11/24 8:05:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Savitz Adam bought $190,833 worth of shares (15,000 units at $12.72) (SEC Form 4)

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/11/24 4:15:04 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Nicholas Conrad bought $100,628 worth of shares (6,150 units at $16.36), increasing direct ownership by 30% to 26,866 units (SEC Form 4)

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      4/1/24 4:15:30 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

      – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

      6/3/25 6:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

      – Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection – – Completed Phase 2a and ongoing Phase 2b trial of ALTO-300 in MDD underscore favorable tolerability profile for 25mg dose – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025. ALTO-300, also known as agomelatine, is an oral, s

      5/29/25 8:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience to Participate in Upcoming Investor Conferences

      Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June: Jefferies Global Healthcare Conference, June 3-5th 2025: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Thursday, June 5, 2025, at 2:00 pm ET Location: New York Marriott Marquis H.C. Wainwright 6th Annual Neuro Perspectives Conference, June 16-17th 2025: Format: Fireside chat and one-on-one investor meetings Presentation avail

      5/28/25 8:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Financials

    Live finance-specific insights

    See more
    • Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

      – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

      6/3/25 6:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alto Neuroscience downgraded by Wedbush with a new price target

      Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

      10/23/24 7:37:30 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience downgraded by Rodman & Renshaw

      Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

      10/23/24 6:52:50 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Alto Neuroscience with a new price target

      Wedbush initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $29.00

      9/3/24 7:41:31 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care